Schizophrenia and schizoaffective disorder treated with high doses of olanzapine

被引：20
|
作者：
Fanous, A [1 ]
Lindenmayer, JP [1 ]
机构：
[1] NYU, Sch Med, New York, NY 10016 USA
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 1999年 / 19卷 / 03期
关键词：
D O I：
10.1097/00004714-199906000-00015
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：275 / 276
页数：2
相关论文
共 50 条
  • [21] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 491 - 491
  • [22] Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Bilder, RM
    Goldman, RS
    Volavka, J
    Czobor, P
    Hoptman, M
    Sheitman, B
    Lindenmayer, JP
    Citrome, L
    McEvoy, J
    Kunz, M
    Chakos, M
    Cooper, TB
    Horowitz, TL
    Lieberman, JA
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (06): : 1018 - 1028
  • [23] Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Virginia L Stauffer
    Jennifer L Sniadecki
    Kevin W Piezer
    Jennifer Gatz
    Sara Kollack-Walker
    Vicki Poole Hoffmann
    Robert Conley
    Todd Durell
    BMC Psychiatry, 10
  • [24] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    Hill, AL
    Tollefson, GD
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 185S - 186S
  • [25] Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy
    Lipkovich, I.
    Deberdt, W.
    Csernansky, J. G.
    Buckley, P.
    Peuskens, J.
    Kollack-Walker, S.
    Zhang, Y.
    Liu-Seifert, H.
    Houston, J. P.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2007, 41 (3-4) : 305 - 310
  • [26] Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder
    Lambert, M.
    Huber, C. G.
    Naber, D.
    Schacht, A.
    Wagner, T. T.
    Hundemer, H. -P.
    Karow, A.
    Schimmelmann, B. G.
    PHARMACOPSYCHIATRY, 2008, 41 (05) : 182 - 189
  • [27] Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
    Stauffer, Virginia L.
    Sniadecki, Jennifer L.
    Piezer, Kevin W.
    Gatz, Jennifer
    Kollack-Walker, Sara
    Hoffmann, Vicki Poole
    Conley, Robert
    Durell, Todd
    BMC PSYCHIATRY, 2010, 10
  • [28] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, B
    Lipkovich, I
    Edwards, S
    Hill, A
    Ahl, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 163 - 163
  • [29] High Correlation Between Serum and Cerebrospinal Fluid Olanzapine Concentrations in Patients With Schizophrenia or Schizoaffective Disorder Medicating With Oral Olanzapine as the Only Antipsychotic Drug
    Skogh, Elisabeth
    Sjodin, Ingemar
    Josefsson, Martin
    Dahl, Marja-Liisa
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (01) : 4 - 9
  • [30] Pre-existing illness severity of schizophrenia patients treated with olanzapine in standard or high doses
    Phillips, G.
    Zhu, B.
    Ascher-Svanum, H.
    Faries, D.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 453 - 454
12345